• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

Merck & Co Inc MRK

Last Price$62.63Day Change (%)-1.49%
Open Price$63.60Day Change ($)-0.95
Day Range62.62–63.7852-Week Range45.69–64.00

As of Wed 8/24/2016 4:50:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. UPDATE: Bull trend intact, latest S&P 500 breakout attempt underway

    UPDATE: Bull trend intact, latest S&P 500 breakout attempt underway

  2. UPDATE: Bull trend intact, latest S&P 500 -2-

    UPDATE: Bull trend intact, latest S&P 500 -2-

  3. Bull trend intact, latest S&P 500 breakout -2-

    Bull trend intact, latest S&P 500 breakout -2-

  4. Bull trend intact, latest S&P 500 breakout attempt underway

    Bull trend intact, latest S&P 500 breakout attempt underway

  5. UPDATE: Stock losses firm as slide in Mylan shares punish health-care sector

    UPDATE: Stock losses firm as slide in Mylan shares punish health-care sector

  6. Osteoporosis Companies Drugs (Merck , Sanofi, Novartis, Eli Lilly and Amgen) Sales & Forecast 2010-2019 - Research and Markets

    Osteoporosis Companies Drugs ( Merck , Sanofi, Novartis, Eli Lilly and Amgen) Sales & Forecast 2010-2019 - Research and Markets

  7. Results from Merck ’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal ...

    Results from Merck ’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine

  8. FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

    FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

  9. Bristol-Myers' stock extends slide after downgrade, Merck upgraded

    Bristol-Myers' stock extends slide after downgrade, Merck upgraded

  10. UPDATE: Failed trial of lung-cancer drug sends Bristol-Myers stock plunging and Merck's shares up

    UPDATE: Failed trial of lung-cancer drug sends Bristol-Myers stock plunging and Merck's shares up

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.